ArticleOcular oncology and pathology2025
Lipid Dominant Toxic Tumor Syndrome.
Article in Ocular oncology and pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The aim of the study was to describe clinical features of lipid dominant toxic tumor syndrome (TTS) and report outcomes following use of intravitreal steroids. Methods: Records of 13 patients who had lipid dominant TTS following treatment of choroidal melanoma with episcleral plaque brachytherapy (EPB) were retrospectively reviewed. Resolution of lipid exudates, subfoveal subretinal fluid, cystoid macular edema (CME), exudative detachment were main outcome measures. Results: Of the 13 patients who developed lipid dominant TTS, 11 (85%) had medium-sized melanomas, and 2 (15%) small-sized melanomas. The average time to onset following EPB was 22 months (range 3-48 months). Seven patients (54%) were noted to have dyslipidemia. The baseline visual acuity at the time of diagnosis of TTS was 50 ETDRS letters (range 10-85). Ophthalmic characteristics were lipid exudates centered around the tumor base in 13 (100%) patients, subfoveal subretinal fluid in 4 (31%) patients, and CME in 2 (15%) patients. Exudative detachment was absent in all (100%) patients. Regressed melanoma was present in all (100%) patients. Eight (62%) patients were treated with intravitreal steroids (4 mg triamcinolone), while 5 patients (38%) were observed. The response to intravitreal steroids was noted in 7(88%) of the treated patients, with the average time to response being 1.9 months. Features characterizing a positive response were reduction in lipid exudates centered around the tumor base (100%), reduction in subfoveal subretinal fluid (100%), and reduction in CME (50%). Cataract development was seen in 10 (83%) and ocular hypertension in 3 patients (23%). Proliferative radiation retinopathy developed in 2 (15%) patients, neovascular glaucoma developed in 1(8%) while no patients required enucleation. Conclusion: The lipid dominant TTS centered around the tumor base that occurs in a radiation responsive tumor could be considered a chronic variant in the spectrum of TTS. Intravitreal steroids in selected cases reverse the course of this variant, stabilizing or improving the vision and avoiding enucleation. Our observations would need to be verified through a larger prospective study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.